NIH

Life Science Industry in California Generates $131 Billion Annually, Providing 1.38M Jobs

Monday, September 27, 2021 - 3:30pm

Biocom California, the association representing the California life science industry, today released a new report showing Californias life science industry provides over 1.38 million jobs in the region, with economic activity generating a total of $131 billion in 2020 alone.

Key Points: 
  • Biocom California, the association representing the California life science industry, today released a new report showing Californias life science industry provides over 1.38 million jobs in the region, with economic activity generating a total of $131 billion in 2020 alone.
  • Biocom Californias 2021 Economic Impact Report highlights these key findings of the states life science industry, including information on economic, demographic, investment and industry performance.
  • San Diego Countys life science industry directly employed more than 72,000 people in 2020, generating $27.7 billion in GRP.
  • Los Angeles County represents nearly 20% of all life science direct employment in California 96,844 direct jobs the largest share of life sciences employment in the state.

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

Monday, September 27, 2021 - 1:00pm

This grant will support the development of DARE-LARC1, Dars investigational user-controlled, long-acting reversible contraceptive (LARC), and such funding is in addition to a separate unrelated grant award for this program of up to $48.95 million announced earlier this year.

Key Points: 
  • This grant will support the development of DARE-LARC1, Dars investigational user-controlled, long-acting reversible contraceptive (LARC), and such funding is in addition to a separate unrelated grant award for this program of up to $48.95 million announced earlier this year.
  • Dar worked with Grant Engine on the development of its grant proposal to the NICHD.
  • Dar plans to continue to pursue non-dilutive funding opportunities to support the further development of its product candidates.
  • Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health.

Sinopia Biosciences Awarded NIH Grant to Support Development of Parkinson’s Disease Pipeline

Monday, September 27, 2021 - 1:00pm

We are pleased to receive funding from the NIH to support the advancement of our Parkinsons disease program towards the clinic, said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences.

Key Points: 
  • We are pleased to receive funding from the NIH to support the advancement of our Parkinsons disease program towards the clinic, said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences.
  • Parkinsons disease affects nearly 7 million people worldwide and is the fastest growing neurological disorder in the world, with the number of patients expected to double by 2040.
  • Its a disease that imposes heavy burdens on patients and caregivers, particularly because current treatments are not optimal and have serious long-term liabilities with chronic use that must be addressed.
  • Sinopia Biosciences, Inc. is a clinical-stage biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform.

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress

Monday, September 27, 2021 - 11:00am

This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).

Key Points: 
  • This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).
  • In CB-refractory advanced cutaneous melanoma, PV-10 may restore disease-specific T cell function, which may also be prognostic of clinical response.
  • IL PV-10 has been administered to over 450 patients with cancers of the skin and of the liver.
  • It is administered under visual, tactile, or ultrasound guidance to superficial malignancies, and under CT or ultrasound guidance to visceral hepatic tumors.

Global HER2 Targeting Therapies Market Trends and Forecasts, 2021-2030 - ResearchAndMarkets.com

Monday, September 27, 2021 - 10:49am

The "HER2 Targeting Therapies Market by Target Disease Indication, Type of Molecule, Type of Therapy and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HER2 Targeting Therapies Market by Target Disease Indication, Type of Molecule, Type of Therapy and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity for HER2 targeting therapies, over the next decade.
  • Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely selling price of HER2 targeting therapies, we have provided informed estimates on the evolution of the market for the period 2021-2031.
  • HER2 targeting therapies have shown to be a promising treatment option, capable of preventing tumor cells from evading immune surveillance.

ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamorolone in Becker Muscular Dystrophy

Monday, September 27, 2021 - 6:05am

The grant adds to existing grants from the National Institutes of Health, NIAMS, and the Foundation to Eradicate Duchenne to initiate a clinical trial of vamorolone in adults and children with Becker muscular dystrophy, a progressive muscle wasting disease similar to Duchenne muscular dystrophy, but usually milder.

Key Points: 
  • The grant adds to existing grants from the National Institutes of Health, NIAMS, and the Foundation to Eradicate Duchenne to initiate a clinical trial of vamorolone in adults and children with Becker muscular dystrophy, a progressive muscle wasting disease similar to Duchenne muscular dystrophy, but usually milder.
  • Vamorolone, a dissociative steroid drug, that has shown retention of efficacy and reduction of safety concerns typically associated with corticosteroids in Duchenne muscular dystrophy (DMD) will now be tested in a 24-week clinical exploratory trial in Becker muscular dystrophy (BMD).
  • The double-blind trial will test efficacy and safety of daily vamorolone on motor outcomes and established biomarker outcomes, with participants randomized 2:1 vamorolone or placebo.
  • ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, September 24, 2021 - 9:05pm

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Gritstones 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Gritstone undertakes no obligation to update or revise any forward-looking statements.

Dr. Mikael Dolsten Named to Agilent Board of Directors

Thursday, September 23, 2021 - 9:05pm

Dr. Dolsten brings 30 years of pharma experience to the Agilent board.

Key Points: 
  • Dr. Dolsten brings 30 years of pharma experience to the Agilent board.
  • Mikaels outstanding scientific, medical and research background makes him a valuable addition to the Agilent board, said Mike McMullen, Agilent president and CEO.
  • Were pleased to welcome Mikael to the Agilent board, said Koh Boon Hwee, chair of the Agilent board.
  • He is a member of the board of directors for Karyopharm Therapeutics, as well as the board at Vimian Group.

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform

Thursday, September 23, 2021 - 7:49pm

WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods. The method was developed in collaboration with the laboratory of Bradley E. Bernstein, MD, PhD through grant R01-HG009269 from the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI).

Key Points: 
  • However, this platform provides multifaceted information in single cell resolution, which will be helpful for cancer diagnosis and assessing its causality.
  • Using this epitranscriptomic method to profile single cells, researchers will have the power to reveal insights into complex biological pathways beyond those that current methods allow.
  • SeqLLs exclusive True Single Molecule Sequencing (tSMS) technology enables direct sequencing of millions of individual molecules.
  • The tSMS platform offers maximum flexibility and avoids many of the challenges common for standard sequencing approaches.

U.S. Intravenous Immunoglobulin Market Analysis Report 2021-2028: Robust Pipeline, Approval and Launch of Novel Products, and Increasing Government Initiatives - ResearchAndMarkets.com

Thursday, September 23, 2021 - 3:55pm

The U.S. intravenous immunoglobulin market size is expected to reach USD 10.24 billion by 2028.

Key Points: 
  • The U.S. intravenous immunoglobulin market size is expected to reach USD 10.24 billion by 2028.
  • Robust pipeline, approval and launch of novel products, and increasing government initiatives are expected to be the major factors driving the market.
  • Robust pipeline and increasing approvals and launches of novel products are anticipated to support the market growth over the forecast period.
  • Furthermore, increasing initiatives by various government organizations to boost the development of novel products are expected to support market growth over the forecast period.